Trial Profile
An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Fedratinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions
- Sponsors Sanofi
- 08 Dec 2020 Results (n=28) of TED12037 and TED12015 studies assessing long-term safety of fedratinib in pts with MF who received > 24 treatment cycles, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 21 Jun 2020 Results (n=28) of open-label, dose-finding and extension studies assessing long-term safety in pts with MF who received >24 cycles of FEDR presented at the 25th Congress of the European Haematology Association.
- 07 Apr 2014 Planned End Date changed from 1 Mar 2014 to 1 Apr 2014, according to ClinicalTrials.gov record.